Zacks Investment Research·Sep 14, 2026
Alaska Air Group (ALK) Declines More Than Market: Some Information for InvestorsAlaska Air Group (ALK) concluded the recent trading session at $40.71, signifying a -1.09% move from its prior day's close.
Alaska Air Group's acquisition of Hawaiian Airlines has expanded its asset base and revenue, but integration costs and accounting reclassifications have clouded profitability, with operating margin swinging from 7.5% in 2025Q2 to -4.1% in 2026Q2. Revenue growt...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth decelerated to 9.7% in 2026Q2, while operating margin turned negative at -4.1%, reflecting integration strain and cost reclassifications that swung gross margin from 25.5% in 2025Q2 to 89.3% in 2026Q2.
Alaska Air Group demonstrated resilience in Q4, with strong unit revenue and better cost management.
The stock has unanimous buy ratings from analysts, with 16 out of 16 recommending Strong Buy or Buy.
Despite leverage risks, analysts project a rebound in earnings per share by 2026.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 21, 2026 | -$0.92+7.3% vs -$0.99 | $4.1B-0.7% vs $4.1B |
Q2 2026 Apr 20, 2026 | -$1.68-1.8% vs -$1.65 | $3.3B+0.2% vs $3.3B |
Q1 2026 Jan 22, 2026 | $0.43+290.9% vs $0.11 | $3.6B-0.3% vs $3.6B |
Q4 2025 Oct 23, 2025 | $1.05-3.7% vs $1.09 | $3.8B+0.2% vs $3.8B |
Alaska Air Group (ALK) concluded the recent trading session at $40.71, signifying a -1.09% move from its prior day's close.
-- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447 in the lung, in line with prior results observed in healthy participants -- -- Robust target engagement of ALK5 observed with AGMB-447 in IPF patients -- -- Clinical Trial Application (CTA) for INSPIRIA Phase 2 study in IPF patients submitted; Company intends to initiate study before year-end -- Antwerp, Belgium, September 14, 2026 – Agomab Therapeutics NV (‘Agomab'), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced positive results of the Phase 1 study of AGMB-447 in IPF patients. AGMB-447 is an investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF).1 The Phase 1 study of AGMB-447 is a three-part, double-blind, randomized, placebo-controlled single ascending dose (SAD; Part A; dose range: 1 mg QD (once daily) to 20 mg QD) and multiple ascending dose (MAD; Part B; dose range: 1 mg QD to 6 mg BID (twice daily)) study in healthy participants and multiple dose study in IPF patients (Part C; dose range: 4.5 mg BID to 6 mg BID).
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company's Executive Vice President and CFO, Claus Steensen Sølje, is scheduled to participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City taking place from 14 - 16 September 2026 on Monday, 14 September 2026, at 3.20 PM EDT.
Hsbc Holdings PLC lowered its stake in Alaska Air Group, Inc. (NYSE: ALK) by 65.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 65,242 shares of the transportation company's stock after selling 122,254 shares during the quarter. Hsbc Holdings PLC
Benchmark ALK against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Alaska Air Group, Inc. (ALK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $41.91 | $4.67B | 48.17 | 21.34% | 0.7% | 2.36% | — | |
| $83.92 | $55.19B | 10.96 | 2.79% | 5.79% | 19.33% | — | |
| $115.21 | $37.39B | 11.27 | 3.52% | 5.56% | 22.5% | — | |
| $13.61 | $9.01B | 80.06 | 0.78% | -0.56% | — | — | |
| $42.08 | $20.59B | 53.27 | 2.11% | 2.78% | 11.27% | — | |
| $4.55 | $1.72B | -2.74 | -2.34% | -9.32% | -45.51% | — |
Alaska Air Group, Inc. (ALK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Alaska Air Group, Inc. (ALK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 21, 2026·SEC
Jun 17, 2026·SEC
Jun 3, 2026·SEC
Get notified when ALK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Alaska Air Group, Inc. (ALK) stock FAQ — growth, dividends, profitability & financials explained
Alaska Air Group, Inc. (ALK) reported $14.76B in revenue for fiscal year 2025. This represents a 827% increase from $1.59B in 1996.
Alaska Air Group, Inc. (ALK) grew revenue by 21.3% over the past year. This is strong growth.
Alaska Air Group, Inc. (ALK) reported a net loss of $175.0M for fiscal year 2025.
Alaska Air Group, Inc. (ALK) has a return on equity (ROE) of 2.4%. This is below average, suggesting room for improvement.
Alaska Air Group, Inc. (ALK) had negative free cash flow of $350.0M in fiscal year 2025, likely due to heavy capital investments.
